TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03195569

Intervention type: DRUG
Intervention: QL1101
Description: targeted vascular endothelial growth factor (VEGF) monoclonal antibodies

Intervention type: DRUG
Intervention: Avastin®
Description: targeted vascular endothelial growth factor (VEGF) monoclonal antibodies

Intervention type: DRUG
Intervention: Paclitaxel
Description: 175 mg/m2, IV following investigational product on day 1 of each 21 day cycle.
Study: NCT00597103

Intervention type: OTHER
Intervention: Periodic Leg Movement Syndrome Assessment
Description: Subjects will wear and Actiwatch on both legs for three consecutive nights.
Study: NCT03195569

Intervention type: DRUG
Intervention: Paclitaxel
Description: 175 mg/m2, IV following investigational product on day 1 of each 21 day cycle.

Intervention type: DRUG
Intervention: Carboplatin
Description: AUC 5 IV, following paclitaxel on day 1 of each 21 day cycle.

Intervention type: DRUG
Intervention: Carboplatin
Description: AUC 5 IV, following paclitaxel on day 1 of each 21 day cycle.
Study: NCT02394561

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Secukinumab was supplied as 150 mg solution in pre-filled syringe for subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Secukinumab was supplied as 150 mg solution in pre-filled syringe for subcutaneous injection
Study: NCT01312831

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B12 (cyanocobalamin)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin B12 (cyanocobalamin)
Study: NCT03728335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enasidenib Mesylate
Description: Given PO
Study: NCT02421757

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fischell Transcutaneous Magnetic Stimulation Pain Treatment Device
Description: Transcutaneous Magnetic Stimulation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo Transcutaneous device
Study: NCT03230188

Intervention type: OTHER
Intervention: functional Magnetic Resonance Imaging (research grade)
Description: Subjects will undergo a simulated and actual functional Magnetic Resonance Imaging scan.

Intervention type: OTHER
Intervention: Cognitive Function Testing (non-diagnostic)
Description: Subjects will take non-diagnostic cognitive function tests

Intervention type: OTHER
Intervention: Asthma and Psychological Questionnaires (non-diagnostic)
Description: Subjects will fill out asthma and psychological questionnaires (non-diagnostic)
Study: NCT01188187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Custirsen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study: NCT03452423

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACRFP
Description: Arthroscopic cartilage regeneration facilitating procedure (ACRFP) is a set of surgical procedures that combines resection of medial plica, medial and lateral capsular release, synovectomy of focal synovitis, and chondroplasty of loosened cartilage flaps as a rationale for the deliberate arthroscopic management of osteoarthritic knee.
Study: NCT00544830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin Acetate
Description: Given SC

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: Given via injection
Study: NCT03433157

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hall technique
Description: Metal Stainless stain crown placed with Hall technique

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional technique
Description: Metal Stainless stain crown placed with Traditional technique
Study: NCT01499654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Half-dose of the Tc99-m sestamibi (Cardiolite)
Description: Researchers will administer half of the radiotracer (Cardiolite), obtain resting images, administer the remainder of the radiotracer and obtain a second set of resting images. Subjects will be given the same amount of radioactive material that would normally be given for this test; however, it will be administered in two ½ doses.
Study: NCT01980641

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: All subjects received an educational intervention consist in an educational advice provides by the therapist to improve the adherence of the treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: All subjects received an educational intervention consist in an educational advice provides by the therapist to improve the adherence of the treatment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone-based application
Description: Smartphone-based application group (SG) sample will have a reminder. The app will provide the advice previously given by the therapist in the participants' homes.
Study: NCT01585558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ospemifene (Dose 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ospemifene (Dose 2)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01188187

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 8 mg by mouth twice a day for 3 days beginning one day before docetaxel administration to reduce the incidence and severity of hypersensitivity reactions and fluid retention.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 8 mg by mouth twice a day for 3 days beginning one day before docetaxel administration to reduce the incidence and severity of hypersensitivity reactions and fluid retention.
Study: NCT00678821

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Supervised aerobic exercise and educational lectures for 10 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise
Description: Supervised aerobic exercise and educational lectures for 10 weeks
Study: NCT05704972

Intervention type: OTHER
Intervention: the operating room environment risk
Description: in determining the risks they face in the operating room environment.
Study: NCT03136406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-fluoro-2,4 (1H,3H)-pyrimidinedione
Study: NCT01731145

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SNUMAP
Description: Portable six-axis (tri-axial accelerometer and tri-axial gyroscope) motion sensing system
Study: NCT02999581

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: C4 Extreme, C4 Extreme (without Advantra Z)
Study: NCT03136406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Recombinant human anti-VEGF IgG1 monoclonal

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: avelumab
Description: Recombinant human anti-PD-L1 IgG1 monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-803
Description: Recombinant human super agonist interleukin-15 (IL-15) complex

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aNK for Infusion
Description: NK-92 cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-011
Description: Ad5 \[E1-, E2b-\]-CEA

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-4000
Description: Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
Study: NCT01468896

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Edodekin alfa
Description: Given SC
Study: NCT02999581

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: C4 Extreme, C4 Extreme (without Advantra Z)
Study: NCT01468896

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02252523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Study: NCT02544542

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rectum cooling system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyper-hypothermia blanket
Study: NCT04081441

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inyenyeri clean cookstove and fuel system
Description: The Inyenyeri cooking systems includes a tier 4 clean cooking system with biomass pellets that are purchased through the unconditional cash transfer program in the refugee camp

Intervention type: DEVICE
Group type: OTHER
Intervention: Inyenyeri clean cookstove and fuel system
Description: The Inyenyeri cooking systems includes a tier 4 clean cooking system with biomass pellets that are purchased through the unconditional cash transfer program in the refugee camp

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inyenyeri clean cookstove and fuel system
Description: The Inyenyeri cooking systems includes a tier 4 clean cooking system with biomass pellets that are purchased through the unconditional cash transfer program in the refugee camp

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I-ACT (Individual, Agency-Centered Training) workshop
Description: The I-ACT (Individual, Agency-Centered Training) empowerment workshop consists of behavioral exercises drawn primarily from positive psychology, that provide the tools to foster a growth mindset by allowing participants to understand the link between their thoughts, beliefs, and past actions to their future actions. Conducted in a workshop setting, this locally adapted version of the I-ACT curriculum consists of two days for women and a 1 day workshop for their male partners (as applicable)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I-ACT (Individual, Agency-Centered Training) workshop
Description: The I-ACT (Individual, Agency-Centered Training) empowerment workshop consists of behavioral exercises drawn primarily from positive psychology, that provide the tools to foster a growth mindset by allowing participants to understand the link between their thoughts, beliefs, and past actions to their future actions. Conducted in a workshop setting, this locally adapted version of the I-ACT curriculum consists of two days for women and a 1 day workshop for their male partners (as applicable)
Study: NCT03669575

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega 7
Description: Three weeks omega 7 fatty acid nutritional supplement, approximately 900 mg/day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: omega 7
Description: Three weeks omega 7 fatty acid nutritional supplement, approximately 900 mg/day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Three weeks placebo fatty acids approximately 900 mg/day which does not contain omega 7

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Three weeks placebo fatty acids approximately 900 mg/day which does not contain omega 7
Study: NCT02404077

Intervention type: DRUG
Intervention: Clonidine
Study: NCT01355718

Intervention type: DRUG
Intervention: repaglinide
Description: The dosage and frequency, as well as later changes to either dose, frequency or add-on medication (if applicable), will be determined by the physician, according to the patient's requirements.
Study: NCT02999581

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: C4 Extreme, C4 Extreme (without Advantra Z)
Study: NCT03749044

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Educational Tool
Description: This tool is a modified version of the patient educational sheet elaborated and validated by You et al in collaboration with the Preeclampsia Foundation. This patient educational sheet graphically defines preeclampsia and its. A licensing agreement has been obtained from the Preeclampsia Foundation, with the rights to modify the educational tool for this RCT. The SLE-specific educational tool will consist in a sheet displaying the previously developed patient educational form on the recto. However, on the verso of the sheet, SLE-specific information related to the risk of preeclampsia in SLE pregnancies and the estimated efficacy of ASA in reducing preeclampsia risk in women at high risk are displayed.
Study: NCT01669512

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Regimen
Description: ChAd63 ME-TRAP 5 x 1010 vp on Day 0 and MVA ME-TRAP 2 x 108 pfu on Day 56

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low Dose Matrix M Regimen
Description: ChAd63 ME-TRAP 5 x 1010 vp mixed with Matrix M-1 25μg on Day 0 and MVA ME-TRAP 2 x 108 pfu mixed with Matrix M-1 25μg on Day 56

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Standard Dose Matrix M Regimen
Description: ChAd63 ME-TRAP 5 x 1010 vp mixed with Matrix M-1 50μg on Day 0 and MVA ME-TRAP 2 x 108 pfu mixed with Matrix M-1 50μg on Day 56
Study: NCT04138056

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: RSVPreF3 formulation 3
Description: One dose of RSVPreF3 formulation 3 vaccine administered intramuscularly in the left or in the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVPreF3 formulation 3
Description: One dose of RSVPreF3 formulation 3 vaccine administered intramuscularly in the left or in the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: RSVPreF3 formulation 3
Description: One dose of RSVPreF3 formulation 3 vaccine administered intramuscularly in the left or in the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVPreF3 formulation 3
Description: One dose of RSVPreF3 formulation 3 vaccine administered intramuscularly in the left or in the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: RSVPreF3 formulation 3
Description: One dose of RSVPreF3 formulation 3 vaccine administered intramuscularly in the left or in the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: RSVPreF3 formulation 2
Description: One dose of RSVPreF3 formulation 2 vaccine administered intramuscularly in the left arm.
Study: NCT03209531

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Operant Conditioning
Description: Active encouragement and feedback to increase motor evoked response when stimulated.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Absence of active encouragement and feedback to increase motor evoked response when stimulated.
Study: NCT00946946

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine placebo
Description: 4g Mesalazine tablets/day AND azathioprine placebo tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalazine placebo
Description: 2.0-2.5mg/kg/BW azathioprine /day and mesalazine placebo tablets
Study: NCT04228120

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-regulation programme
Description: The programme consisted of one 20-to-30-minute, face-to-face individual education session related to self-regulation and problem-solving processes that was performed in accordance with the patient's plan. Furthermore, eight 15- to 20-minute telephone follow-up counselling sessions were delivered twice per week for four weeks.
Study: NCT00235339

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: Standard exercise training at the hospital, two times per week for twelve weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Interval exercise training with high intensity on treadmill. Subjects exercise two times per week for twelve weeks
Study: NCT04282304

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Preoperative usual care
Description: Usual care during the preoperative preparation for bariatric surgery consists of:~* Endocrinologist work-up and follow-up, with at least 2 consultations;~* Dietary advice, provided during the endocrine consultation or dietician consultation~* Psychological counselling with the patient's usual psychiatrist (at least 2 consultations~* Physical activity and nutrition are encouraged, but entrusted to the patient's freedom of choice. Weight loss, or at least, weight stabilization, is recommended before the surgery, without initiating a specific behavioural procedure.
Study: NCT02300415

Intervention type: BIOLOGICAL
Intervention: blood sample
Description: Dosage of presepsine
Study: NCT04282304

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preoperative intensive behavioral lifestyle intervention
Description: The intensive behavioral lifestyle intervention program takes place over 4 weeks of 5 days. It includes:~* Rehabilitation to physical exercise every morning~* Therapeutic cooking sessions; during these sessions, the patients prepare the day's meals under the supervision of a nutritionist~* Psychological counselling~* One swimming session per week~* One relaxation session~* Regular physical activity (aerobics, work-up)~* Individual entertainment with the physiotherapist physician and discussion groups~* Weight, BMI and waist circumference control at the end of each week.
Study: NCT03031444

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab plus FOLFIRI/FOLFOX
Description: cetuximab was added into the routine perioperative chemotherapy(FOLFIRI/FOLFOX) to evaluate its safety and efficacy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI/FOLFOX/CapeOX
Description: to evaluate its safety and efficacy of routine perioperative chemotherapy(FOLFIRI/FOLFOX/CapeOX)
Study: NCT02994654

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReCell
Description: The ReCell-assigned treatment area will be treated as described in the product's Instructions for Use. In summary, 1ml of fluid physically covers a treatment area of 80 cm2. Each milliliter of fluid contains cells harvested from a square centimeter of thin split-thickness skin sample.~The reagents and components of the ReCell kit are used, in a scalable fashion, to facilitate disaggregation of cells from skin samples into filtered cell suspension. Areas to be harvested for skin samples are to be clean and show no evidence of surrounding cellulitis or infection. Treatment area sizes and cell suspension volumes are to be recorded.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReCell
Description: The ReCell-assigned treatment area will be treated as described in the product's Instructions for Use. In summary, 1ml of fluid physically covers a treatment area of 80 cm2. Each milliliter of fluid contains cells harvested from a square centimeter of thin split-thickness skin sample.~The reagents and components of the ReCell kit are used, in a scalable fashion, to facilitate disaggregation of cells from skin samples into filtered cell suspension. Areas to be harvested for skin samples are to be clean and show no evidence of surrounding cellulitis or infection. Treatment area sizes and cell suspension volumes are to be recorded.
Study: NCT04284956

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Proximal and distal segment of saphenous vein harvested by No-Touch technique
Description: two longitudinal incisions are made on the thigh and shank from unilateral lower limb (for harvesting of proximal segment of saphenous vein, incision is started from about 3 or 4cms inferolateral to the pubic tubercle and then extended downward). As previous reported. the adventitia and perivascular tissue are carefully kept intact to avoid damage. Then a margin of about 5 mm from both sides of the vein is created to include the fat pedicle using electrocautery, and all visible side branches are ligated with 4-0 silk or by metal clipping (branches are divided at the pedicle margin rather than the vein trunk). The saphenous vein is then separated from its bed using scissors and electrocautery, together with surrounding tissue.
Study: NCT04138056

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVPreF3 formulation 2
Description: One dose of RSVPreF3 formulation 2 vaccine administered intramuscularly in the left arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix-ex-US
Description: One dose of the dTpa (Ex-US formulation) vaccine administered intramuscularly in the right arm.
Study: NCT04284956

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Proximal and distal segment of saphenous vein harvested by No-Touch technique
Description: two longitudinal incisions are made on the thigh and shank from unilateral lower limb (for harvesting of proximal segment of saphenous vein, incision is started from about 3 or 4cms inferolateral to the pubic tubercle and then extended downward). As previous reported. the adventitia and perivascular tissue are carefully kept intact to avoid damage. Then a margin of about 5 mm from both sides of the vein is created to include the fat pedicle using electrocautery, and all visible side branches are ligated with 4-0 silk or by metal clipping (branches are divided at the pedicle margin rather than the vein trunk). The saphenous vein is then separated from its bed using scissors and electrocautery, together with surrounding tissue.
Study: NCT01597427

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Clonidine
Description: Administration of 2 μg/kg of intravenous clonidine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection of placebo solution.
Study: NCT02426060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imrecoxib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin